Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 25, 2025Frontiers in OncologyOpen Access

Predictive role of MGMT and IDH status in the efficacy of bevacizumab for high-grade glioma: a retrospective study

View Full Paper
Ask AI
Bookmark
Share

Authors

BXBai XuexueCYChengrui YanWMWenbin Ma

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows MGMT and IDH influence survival rates in glioma patients treated with bevacizumab, indicating their importance as biomarkers.

Key Points

  • Higher progression-free survival and overall survival are noted in high-grade glioma patients with MGMT methylation.
  • IDH mutation status is associated with improved therapeutic response in patients undergoing bevacizumab treatment.
  • The study employed multivariate Cox regression to assess survival factors in a cohort of 103 patients.
  • Findings suggest common biomarkers like MGMT and IDH could guide treatment strategies for glioma.

Cite This Study

Xuexue et al. (2025) studied this question.

synapsesocial.com/papers/68af5f07ad7bf08b1eae174chttps://doi.org/10.3389/fonc.2025.1634892
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Correlation between MGMT methylation and the efficacy of bevacizumab in high-grade glioma2025
  2. 2Correlation between MGMT methylation and the efficacy of bevacizumab in high-grade glioma2025
  3. 3Clinical and radiographic prognostic factors in recurrent contrast-enhancing IDH-Mutant Gliomas treated with Bevacizumab2026
  4. 4MGMT promoter methylation in prognosis of patients with newly diagnosed IDH1 wildtype Glioblastoma2024
  5. 5Clinical impact of IDH1 mutations and MGMT methylation in adult glioblastoma2024 · 4 citations